Trials / Completed
CompletedNCT05006742
Comparison of Transbronchial Cryobiopsy and Forceps Biopsy in Lung Transplant Recipients
Comparison of Transbronchial Cryobiopsy and Forceps Biopsy in Lung Transplant Recipients: A Prospective Analysis for Acute Cellular Rejection
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- University of Zurich · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
CLAD is defined as loss of lung function after other factors, particularly infections have been excluded. Readily accessible diagnostic procedures to detect acute cellular rejection at the earliest possible occasion is crucial for posttransplant survival. Serial lung function tests, laboratory testing and pulmonary imaging are only clinical indicators of chronic allograft dysfunction in lung transplant recipients. Since forceps biopsy to detect acute cellular rejection in lung transplant recipients has several shortcomings, the purpose of this study is to investigate a new biopsy technique using the transbronchial cryoprobe.
Detailed description
Eventually, histopathological confirmation is indispensable to establish the diagnosis of acute cellular rejection. The current gold standard for diagnosis and grading of acute cellular rejection in order to initialize the optimal treatment, with particular regard to adjusting immunosuppression, is forceps biopsy to obtain ≥ five samples. Forceps biopsy has a reasonable risk profile in experienced centers and is performed 2, 4, 6 and 12 months posttransplant and when indicated. Given these concerns about diagnostic yield in forceps biopsy and unjustifiable risks after surgical lung biopsy, cryobiopsy has arisen as promising alternative diagnostic procedure. The value of cryobiopsy to obtain a conclusive diagnosis of ACR is discussed controversially due the lack of safety and efficacy data in lung transplant recipients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | CB study arm | Included patients are randomized to receive cryobiopsy |
| PROCEDURE | FB-CB study arm | Included patients are randomized to receive forceps biopsy and cryobiopsy within the same session |
Timeline
- Start date
- 2021-05-07
- Primary completion
- 2024-01-31
- Completion
- 2024-02-28
- First posted
- 2021-08-16
- Last updated
- 2024-06-28
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT05006742. Inclusion in this directory is not an endorsement.